A Phase II Study of Apatinib in STS Patients

Sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Study ID
NCT03064243
Phase
PHASE2
Status
Unknown

Conditions

  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Apatinib is a kind of innovative medicines approved by China Food and Drug Administration（CFDA）, which was researched by Jiangsu Hengrui Pharmaceutical Co., Ltd. Apatinib is a kinase inhibitor of receptor tyrosine with VEGFR2. The protocol is to explore Apatinib for the effectiveness of advanced soft tissue sarcoma and safety.

Key Dates

Start date
Mar 1, 2017
Status verified
Feb 2017
Primary completion
Mar 1, 2018
Completion
Sep 1, 2018

Study Design

Enrollment
53 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib group
    apatinib 500mg po qd

Primary Outcome Measure

6 months PFS rate [ Time Frame: From baseline to 6 months ]

Related Studies